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ABSTRACT
Background and Significance: The Hispanic population is disproportionally affected by
T-ALL (T-cell acute lymphoblastic leukemia) when compared to other races in the US. C-C
Chemokine Receptor 7 (CCR7) in T-ALL is used during disease progression, and may lead to
migration of cancerous cells into the Central Nervous System (CNS) of patients. Goals and
Objectives: This project aims to find relevant rates and risk factors for T-ALL for the Hispanic
population in the US/Mexico border region. The other aim is to assess the effect of the G proteincoupled Receptor Kinase 4 (GRK-4) family proteins on migration and receptor internalization
through CCR7 in T-ALL. Hypothesis: The inactivation of the GRK-4 family genes (specifically
GRK-5 and -6) in cancerous cells (CEM and Hut-78) will produce a reduction in CCR7-directed
migration of these T-ALL cells towards the CCR7 ligands CCL19 and/or CCL21. Methods:
Local, state, and national health data agencies were queried for relevant rates of, and data about
T-ALL in Hispanics living in the US/Mexico border region. GRK-5, and -6 genes were
individually targeted using CRISPR-Cas9 in T-ALL cells to inhibit protein expression. Results:
Data about T-ALL in the border region and the city of El Paso is scarce and has discrepancies
among different agencies. Leukemias are the most common cancers in children 0 to 20 years of
age, and the Hispanic population is more heavily affected than the non-Hispanic White
population according to some sources. The expression of GRKs was not reduced with the
CRISPR lentivirus approach, but it was somewhat reduced through esiRNA nucleofection.
Conclusions: T-ALL is tied to several environmental factors and living conditions that apply to
the Hispanic population in the US/Mexico region. Preventing the incidence of this disease
requires health awareness interventions and safety regulations in industries where workers are
exposed to, or handle leukemogens. The CRISPR-Cas9 experimental results showed no
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reduction in the expression of GRK-5 or -6, but GRK-6 was partially reduced after esiRNA
nucleofection, which could provide an alternative to test the chemotactic and internalization
properties of cells once these kinases are inhibited.
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CHAPTER 1: LITERATURE REVIEW
BACKGROUND
The city of El Paso, Texas is located along the United States-Mexico border and its
population is predominantly of Hispanic descent (82.8%) (US Census Bureau, 2017). The
Hispanic population has been documented to be disproportionally affected by diseases such as
diabetes, cardiovascular disease, and several types of cancers when compared to other races in
the United States (Rodriguez, 2014; Aviles-Santa, 2017; Center for Disease Control and
Prevention, 2017). Epidemiological data shows that cancer incidence and mortality rates have
increased over the last decades for all races in the country (Barrington-Trimis, 2015, American
Cancer Society, 2018), however, there has been a significant increase in the incidence of Acute
Lymphoblastic Leukemias (ALLs) within the Hispanic population at younger ages (<20 years of
age) when compared to other non-Hispanic individuals (Darbinyan, 2008; Barrington-Trimis, 2015
Bencomo‐Alvarez, 2020). Some factors like living conditions, socio-economic levels, education,
health awareness, risk behaviors, culture, nutrition, pathology, genetics, and other variables are
known to influence the risk perception, incidence, progression, and treatment of different forms
of cancers for different populations (Aviles-Santa, 2017; Siegel, 2017).
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Figure 1. Age-adjusted incidence rate for Hispanic and non-Hispanic children from 1992-2011 in the United States.
(Barrington-Trimis, 2015)

The Texas Cancer Incidence Reporting Act requires local hospitals, clinical laboratories,
and physician practices to report cancer cases according to the Texas Health and Safety Code
Section 82.007, but reporting requirements vary depending on the facility (Texas Department of
State Health Services, 2019; 2020). Some of the agencies that collect relevant health data are:
The Healthy Paso del Norte Foundation, the Texas Department of State Health Services, the
Texas Cancer Institute, and the Healthy People 2020 organization. These agencies have recorded
data at the local, state, and national levels, and they are updated as the years pass or as progress
is made on specific organizational objectives. To date, there are few registries with current and
comprehensive information about ALLs, and there is a specific lack of data on studies about Tcell ALL (T-ALL) in large pediatric groups (Fuhrman, 2018). The Surveillance, Epidemiology,
and End Results Program (SEER) database was created by the National Cancer Institute, and it is
considered the “gold standard” for population-based research, despite a few caveats (Howlader,
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2020; Kinslow, 2020). SEER is based on the insurance claims of some specific regions and states

in the country (Texas is not included), which means that it may not accurately represent all
populations in the United States. Another consideration is that its data has differences with the
other previously mentioned sources of health data. These differences, and the lack of data
collection in some regions/states could be underrepresenting the severity of ALLs for the
different population groups in the country. This suggests the need for public health interventions
and preventive screening services, but there are specific problems in the border region that
further complicate these efforts. The US-Mexico border is one of the busiest in the world, and it
has had increasing problems with illegal immigration and other related regional issues (Healthy
Border 2020, 2015). Illegal immigration status, the fear of deportation, the lack of insurance,
lower socioeconomic status, language barriers, and access to care have been documented as the
basis for the lack of people seeking medical attention and/or participating in health programs
(Bickell, 2008; American Cancer Society, 2018; Healthy Border 2020, 2015; Bencomo‐Alvarez,
2020). These local issues require more extensive planning, prevent the proper utilization of
health programs, and ultimately affect intervention efforts in the region.
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Figure 2. Age-Adjusted Invasive Cancer incidence rates in Texas by county (2012-2016). (Texas Cancer Registry,
2019).

There are many factors that influence the incidence and prevalence of cancer, among
them there are inherent factors which cannot be controlled like genetic predispositions, ethnicity,
gender, and age. However, there are other factors such as risk behaviors, nutrition, health
awareness, and to some degree socioeconomics, education, and the environment, which can be
modified to improve the health and quality of life of a population (American Cancer Society,
2018; Aviles-Santa, 2017; Siegel, 2017). Public health programs and interventions can help
initiate these improvements, but they require comprehensive research and needs assessments to
identify the current health problems in a region and populations of interest. These studies can
help identify baseline measures, and barriers that should be considered when designing an
intervention program for a given community. The collection of data about ALL’s would allow
the city of El Paso to create disease registries that accurately document the local burden of
4

disease and help identify the risks factors that may be predisposing this population to develop
these types of cancers. Collecting local population-based data would also be a good way to
identify treatment-related outcomes (Kinslow, 2020) and could also help promote awareness of
risk factors in the region.
Healthcare interventions can be reinforced by involving both the healthcare providers and
the patients/community for the improvement of health conditions. Introducing cultural
competence, improving health literacy, and increasing access to health programs can reduce
health disparities by making patients feel more comfortable and willing to follow medical advice
(Kagawa-Singer, 2010; Rodriguez, 2014; Winestone, 2019). Preventive practices, health
awareness, and screening programs could be enhanced through collaboration between
community leaders, medical ethicists, and activists who are actively engaged within their
communities. These joint efforts would be effective in educating the general public by
integrating patients and local community leaders in the promotion of healthier lifestyles and safer
behaviors for their communities (Rodriguez, 2014; ACS, 2018). These approaches reinforce the
communication between patients and doctors, encourage proper consultation of medical advice,
reduce barriers to medical treatment (and increases adherence to it), and ultimately reduce health
disparities among the population (Bickell 2008; Winestone, 2019). The combined data collected
from researchers, data registries, public health professionals, physicians, community activists,
and patients could be used to develop more complete strategies to promote health awareness and
preventive screening for ALLs.
The mechanisms of cancer development and progression have been extensively
investigated and are continuously updated to map the specific cellular pathways that generate
and sustain malignancies. Different types of cancers are induced by distinct genetic mutations
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and/or dysregulated cellular processes, which ultimately alter the homeostatic physiological
functions of cells. The accumulation of these genetic mutations converts cells into a malignant
state by activating oncogenes, deactivating tumor suppressor genes, and dysregulating cellular
growth patterns that can ultimately become tumors/malignancies with additional health
consequences (Grabher, 2006; O’Hayre, 2014; Korbecki, 2020). The technical details about the
specific mechanisms that promote T-ALL progression may be of little significance to the lay
population of El Paso, but a more thorough understanding of the etiology of the disease can help
improve current treatment options, which would ultimately improve survival rates, and increase
public health awareness and education in the El Paso/Juarez region and other border
communities. This project aims to define the function of some mediators of T-ALL signaling
pathways, specifically the G-Protein Coupled Receptor (GPCR) C-C Chemokine Receptor type 7
(CCR7). This pathway is important for T-ALL progression because CCR7 expression has been
consistently observed in tissue samples from patients with this disease (Buonamici, 2009;
Korbecki, 2020).
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INTRODUCTION
GPCRs are the largest family of cell-surface receptors (>800) in humans that modulate
many physiological functions (neurotransmission, cardiac activity, blood pressure, homeostasis,
metabolism, sensory perception, immune response, and growth processes, among others) in
virtually all cells. GPCRs are expressed in species ranging from Homo sapiens to Metazoans
(animal) (Premont, 2007; Zhukovskaya, 2013; Heldin, 2016; Korbecki, 2020). Signaling through
GPCRs is just one type of signaling system used by cells to adapt to their environment, however,
there are other signaling systems through other types of receptors and channels in cells (Heldin,
2016). The general structure of GPCRs consist of 7 transmembrane α-helices which span the
extracellular and intracellular faces of a cell membrane. Once a GPCR binds to an extracellular
ligand, a conformational change is triggered in the intracellular face of the α-helices of the
GPCR and the C-terminus becomes a “Guanosine Exchange Factor” (GEF). This “GEF”
regulates exchange of guanosine triphosphate (GTP) on the associated G-proteins, which are an
assembly of 3 different (heterotrimeric) subunits (Zhou, 2017). There are G-protein alpha (Gα),
beta (Gβ), and gamma (Gγ) subunits, and each of them has several genetic variants (Premont
2007; Syrovatkina, 2016). To date, 16 to 21 Gα isoforms (organism specific), 6 Gβ isoforms, and
12 Gγ isoforms have been identified, although new ones continue to be described (Minh Duc,
2015; Zhou 2017). When the G-proteins are in their “inactive” state, the 3 subunits are bound in
the heterotrimeric (G-α, β/γ) conformation. While in this inactive state, the G-alpha (Gα) subunit
is bound to a guanosine-5’- diphosphate molecule (Gα-GDP), and the G-beta-gamma (Gβ/γ)
subunits are almost always bound to each other and are considered a joint functional unit. This
allows for many possible combinations of G-protein subunit complexes, which can interact with
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numerous GPCRs, and together are responsible for modulating numerous cellular signaling
events.

Figure 3. General GPCR ligand-mediated recycling and degradation pathways in a cellular membrane
(Zhukovskaya, 2013).

To activate the G-proteins, the heterotrimeric complex must exchange GDP for GTP. The
activated (ligand-bound) GPCR will function as a “GEF” to promote the exchange of the GDP
bound to the Gα subunit for GTP (Figure 3), this will dissociate the heterotrimer into its “active”
subunits Gα-GTP and Gβ-γ. These subunits can then signal via other specific downstream
effectors. Different organs and tissues require the expression of specific groups of GPCRs, which
are activated by specific ligands that are required for their specialized functions (Hubbard, 2005;
Korbecki, 2020). The many possible combinations of G-proteins and GPCRs serve as “rheostats”
for the control and regulation of many important physiological functions in mammalian cells,
such as allowing them to perceive and respond to different types of stimuli from their
environments (Hildebrandt, 1997; Svoboda, 2004; Syrovatkina, 2016).
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Figure 4. G-protein αβγ subunits and some of their downstream signaling cascades (Heldin, 2016)

As mentioned, the interaction of a GPCR with its cognate ligand produces a GEF in the
cytoplasmic side of the membrane, which interacts with G-protein heterotrimers to activate
downstream signaling (Premont, 2007) (Figure 4). Homeostatic cellular functions require precise
signaling control to prevent undesired processes (McNamee, 2014). To regulate these signals, the
GTP of the active Gα-GTP subunit can be hydrolyzed to a Gα-GDP. GTPase Activating Proteins
(GAPs) can accelerate this hydrolysis, so that Gα-GDP subunits bind to, and reform
heterotrimers with available G-βγ subunits, and reform an inactive heterotrimer, which is able to
bind to a free receptor (Hubbard, 2005; Litosch, 2016). These events modulate G-protein
signaling depending upon stimuli from the environment or physiological functions.
Another way of regulating G-protein signaling is by proteins that directly phosphorylate
the ligand-bound GPCR to sterically hinder further binding with G protein heterotrimers. The
9

major family of these receptor-phosphorylating proteins is the G-Protein Coupled Receptor
Kinase (GRK) superfamily, which can promote internalization of GPCRs and their bound
ligands (Zhukovskaya, 2013). GRK’s require specific interactions with intracellular substrates to
be activated and recruited to a GPCR, and this can be signaled by some of the previously
activated G-proteins and/or other subsequent downstream effectors along a particular GPCRligand pathway (Ribas, 2007; Boguth, 2010; Zhukovskaya, 2013). GRKs phosphorylate the
serine and threonine residues of the ligand-bound GPCRs, although the GRKs can also interact
with other substrates in the cell by phosphorylation-independent processes (Chen, 2009, 2011;
Gurevich, 2012). The phosphorylated GPCR then recruits other proteins for internalization and
signaling, such as beta-arrestins, which bind to the phosphorylated serines and/or threonines on
the cytoplasmic loops and/or C-terminus of the GPCRs (Ribas, 2006). The recruited arrestins
cluster and cap the receptor on the internal face of the cell membrane, and along with other
recruited proteins, they contribute to the internalization of the GPCR. However, arrestin
independent pathways for GPCR internalization also exist (Bychkov, 2012, Heldin, 2016). After
internalization, the GPCR-ligand complex can be targeted for degradation (desensitization of the
cells surface) or recycling (re-exposure at the cell surface), both of which are dependent on
specific GPCRs and ligands, types of cells and tissues, GRKs, and other recruited proteins of
signaling cascades (Svoboda, 2004; Moore 2007; Raghuwanshi, 2013). Ultimately, the
internalized receptor and its destination in the cell is meant to signal a specific function in that
given cell.
There are 3 subfamilies within the GRK superfamily. The first discovered was the
“optical” subfamily which includes a rhodopsin kinase (later termed GRK-1) and GRK-7 (a
kinase specific for cone receptors), and they are both found only in the eyes (Ribas, 2006;
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Moore, 2007; Zhukovskaya, 2013). Second, there is the beta-adrenergic (β-AR) subfamily that
includes GRK-2 and GRK-3 (Ribas, 2006; Moore, 2007; Zhukovskaya, 2013). These subtypes
are ubiquitously expressed among mammalian cells and were later found to have similarities in
genomic sequence, structure, and function to GRK-1, which led to the identification of the GRK
superfamily (Gurevich, 2012). The last group discovered was the GRK-4 subfamily which
includes GRK-4, GRK-5, and GRK-6 (GRK-4 is expressed in testes, kidneys, and brain, and
GRK-5 and GRK-6 are ubiquitously expressed in many types of cells) (Matsubayashi, 2008;
Mushegian, 2012). The general structure of all seven GRKs is composed of three main structural
domains, but these regions have variations among them depending on the particular GRK
subtype (Figure 5) (Gurevich, 2012; Zhukovskaya, 2013). Each GRK is composed of
approximately 500 amino acids, and phylogenetic studies indicate that the most ancestral
subfamily is the beta-adrenergic (β-AR) subgroup (Mushegian, 2012). The other two subfamilies
are predicted to have evolved later after genetic branching into what became the GRK-1 and
GRK-4 subfamilies.
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Figure 5. GRK genetic domains among the GRKs subtypes (Gurevich, 2012)

The ligand CCL21 is produced in High Endothelial Venules (HEV) of lymph nodes and
other secondary lymphoid tissues of the lymphatic system (Jorgensen, 2017). The ligand CCL19
is produced by activated dendritic and stromal cells inside the lymph nodes (Shannon, 2012).
Both ligands create a chemokine (chemotactic-cytokine) gradient in the HEVs of the lymphatic
system, however, each of these ligands produces a specific effect through subsequent
downstream signaling in the cell. CCL21 induces chemotaxis of “immature” T-cells into lymph
nodes and other secondary lymphoid organs; then CCL19 promotes naïve T-cell differentiation
into mature T-cells following interactions with activated antigen presenting cells (APC) (Byers,
2008; Shannon, 2010). This system activates the adaptive immune response of an organism once
an antigen is captured by the APCs of a host; and its optimal function requires precise control of
cellular signaling events to mount an effective immune response.
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Figure 6. Migration of T-cells to chemokine gradients of CCL19 and CCL21 in HEVs of a lymph node (Comerford,
2013).

Cells regulate the downstream effects of a specific ligand-GPCR interaction through Gproteins, Regulators of G-protein Signaling (RGS), GAPs, and GRKs, all specific to particular
pathways (Svoboda, 2004; Litosch, 2016). If the activated GPCR is phosphorylated and
internalized, the following downstream pathways taken by the GPCR-ligand complex will differ
depending on the specific complex (CCR7-CCL21 or CCR7-CCL19). The recycling or
degradation of these complexes will ultimately signal a particular function in each cell, such as
chemotaxis or growth/differentiation (Bar-Shavit, 2016).
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Figure 7. G-α proteins activated by CCL19 and CCL21 through CCR7 and their downstream effects (Jorgensen,
2018).

Some GRK isoforms can replace or “rescue” the activity of a missing GRK in
experimental conditions, but the ultimate effect (mechanism) on the cell is not the same as it
would be with the canonical GRK interaction (Ribas, 2006). To delineate the function of a GRK,
their individual genes can be “knocked-out” (deleted) or disrupted in a cell line to limit or block
protein expression, to compare the effect of stimulating a receptor of interest under controlled
conditions (with and without the interaction of a specific GRK). Such studies have shown that
each GRK has specific regulatory mechanisms in different receptors, cells, and diseases, which
can be attributed to the loss of function or increased activity of a particular GRK (Fong, 2002).
GRK-4 has been linked to the promotion of breast cancer cell growth (Matsubayashi, 2008).
GRK-5 can mediate phosphorylation dependent signaling in cardiac output, but also other
phosphorylation independent processes that remodel neuronal cytoskeletons (Chen, 2011;
Gurevich, 2012). The inhibition of the GRK-6 gene can increase the severity of arthritis, gut
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inflammation, and tumor size of Lewis lung cancer cells used in mice models of disease (Terrant,
2008; Raghuwanshi, 2013; McNamee, 2014). Many experiments have demonstrated a significant
involvement of each GRK subtype in the regulation of GPCRs processes, and some of the
dysregulation in these signaling systems can be linked to specific pathological symptoms
observed in medical conditions and diseases.
GPCR signaling can be subjected to disturbances caused by genetic predispositions and
disease, but also by the environment, lifestyle, and drugs/medicines (Desai, 2017; Siegel, 2017;
Zhao, 2016). This implies that the mechanisms that drive cancer progression have distinct
dysregulation in different individuals and cells in response to receptors and downstream effectors
during disease progression. Also, this suggests that by understanding the role of GRKs in the
regulation of receptor internalization and chemotaxis signaling, we could develop a better
understanding of the etiology of T-ALL through the CCR7 pathway. The mediators of interest in
this project will be the GRK-4 subfamily members (GRK-5, 6) since they have physiological
significance in the incidence and proliferation processes in several types of malignant tumors.
GRK-4 expression has been linked to lymph node metastasis and tumor survival (Matsubayashi,
2008; Tiedemann, 2010), GRK-5 has been linked to the aggressiveness of Gliomas (Kaur, 2012),
and GRK-6 is highly expressed in myelomas and lymphoid cells, and its inhibition reduced
migration of T-cells through some GPCR pathways (Lefkowitz, 2008; Tiedemann, 2010).
The cognate ligands for CCR7 are the chemokines CCL19 and CCL21, these activate Gprotein signaling and downstream effectors that promote receptor internalization. This leads to
chemotaxis and/or differentiation of immature T-cells in secondary lymphoid tissues, which will
ultimately mount an effective immune response when activated properly (Charest-Morin, 2013;
Purvanov, 2018). However, the dysregulated CCR7 pathway has been linked to the progression
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of T-ALL by altering the migration and differentiation signals of T-cells (Bar-Shavit, 2016;
Boire, 2017; Wang, 2019).
Altered gene expression can lead to malignancies (Weng, 2004; Bounamici, 2009;
Heldin, 2016; Triplett, 2016). T-ALL is a neoplasm of immature T-cells (lymphoblasts), and the
dysregulation of CCR7 expression leads to CNS invasion, which results in very poor prognoses
(Bounamici, 2009; Boire, 2017; Wang, 2019). The goal of this project is to better understand
how GRKs affect T-cell migration during leukemic metastasis. Therefore, we will examine the
functions of GRK-5 and GRK-6 in two human T-ALL cell lines: CEM [CCRF CEM]
(ATCC® CCL119™) and Hut-78 (ATCC® TIB161™), which are human T-cells from two
different patients, which express CCR7 (ATCC, 2016). We anticipate that understanding the
mechanisms that lead to CNS invasion in T-ALL will improve our understanding of its etiology.
This could identify molecular targets along the CCR7 pathway that can be therapeutically treated
to improve outcomes of patients with this disease.
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PROBLEM STATEMENT
The incidence and progression of cancer, specifically T-ALL, is driven by cellular
mechanisms that are presumed to be disrupted, leading to the transformation of healthy cells into
cancerous cells. The immune system relies on highly specific cellular mechanisms for the
effective regulation of T-cell physiology which contributes to mount an adaptive immune
response; but many factors (genetics, pathology, stress, activity level, nutrition, drugs,
environment, and living conditions) can dysregulate homeostatic gene expression (Genua, 2015;
Kaur, 2012; McNamee, 2014; Zhao, 2016; Siegel, 2017). The expression of oncogenes, and their
downstream signals can increase and/or decrease the production of receptors, metabolites, tumorsuppressors, blood vessels, and chemokines/interleukins for the proliferation of cancerous
cells/tumors in local microenvironments (Oka, 2020; Yuan, 2013). In general, T-ALL cells have
genetic mutations in genes such as NOTCH-1, PI3K, AKT, JAK-STAT, and PTEN, that are
thought to lead to different cancers (Weng, 2004; Szarzynska-Zawadzka, 2019; BencomoAlvarez, 2021). This signaling disrupts the homeostatic cellular functions of T-cells and can lead
to disease progression (differentiation, division, and migration) (Grabher, 2016; SzarzynskaZawadzka, 2019).
T-cells require the gene NOTCH-1 during differentiation, but it has also been linked to TALL tumorigenesis (Weng, 2004; Triplett, 2016). In 80% of cases, T-ALL cells upregulate
NOTCH-1 which correlates with increased expression of CCR7 (Buonamici, 2009). Chemokinemediated migration to CCL19 and CCL21 becomes problematic when malignant T-ALL cells
are directed to tissues to which they can adhere or infiltrate, and can cause further complications.
Some of the most frequent tissues affected are the bone marrow, mediastinum, pleura/lungs,
skin, and lymph nodes which can progress to peripheral T-cell lymphomas (PTCL), but the most
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dangerous cases involve the CNS which can lead to Primary Central Nervous System
Lymphomas (PCNSL) (Gokbuget, 2011; Gleeson, 2017; Han, 2017).
The CNS is protected by a blood-brain barrier (BBB) that separates the meninges and
CNS lymphatics from the rest of the circulatory system. This barrier-epithelium is tightly
designed to restrict the access of most cells and macromolecules into the CNS under homeostatic
conditions (Boire 2017). The BBB makes the leptomeningeal spaces of the CNS mostly
inaccessible, and these spaces are also poor growth environments for cells. However, studies
have shown that cancerous dendritic cells can promote disruption and infiltration of this barrier
by adapting the surrounding microenvironment, and making it a more conducive media to
promote other malignant cell invasion and proliferation (Triplett, 2016; Boire, 2017; Louveau,
2018). T-ALL expression of CCR7 has been linked to the infiltration of the BBB/CNS because
these cells, which have chemotactic activity towards CCL19, are found in the brain venules close
to infiltrated lymphocytes (Buonamici, 2009). T-ALL patients have very poor prognosis when
left untreated since 30-70% of them develop CNS infiltration, and usually succumb to disease
within 6-8 weeks after diagnosis (Boire, 2017; Han, 2017; Yao, 2018). Almost 50% of adult Tcell Lymphoma cases patients die within 6-12 months, despite treatment (Oka, 2020).
There are different treatment options against cancer, but they all depend on the type and
the stage when it is first detected. The current therapeutic options are chemotherapy,
radiotherapy, and surgical resection, although each option has specific considerations. Systemic
chemotherapy consists of infusing the patient with cytotoxic drugs/cocktails, (such as
cyclophosphamide, doxorubicin, epirubicin, methotrexate, 5-fluorouracil, etc.) that circulate
through the patient’s blood system. This option has improved the 5-year survival rate of children
with T-ALL to 75%, but patients who experience treatment failure or relapse have poor

18

prognosis and are largely incurable (Triplett, 2016; Wang, 2019; Wada, 2020). Initially patients
experience side effects due to the non-specific toxicity of the drugs, which kills most circulating
T-cells (healthy and/or cancerous). Chemotherapies such as methotrexate deplete the host
defenses by killing immune cells in the circulation and leaving the immune system compromised
against infections. At this point, patients may need to abort their 2–3-year regimens just to
survive. Moreover, long-term immunosuppression is a major risk factor for PCNSL (Milgrom,
2014). Chemotherapies also provoke the heterogeneous expression of genes in cancerous cells,
which promote the development of multi-drug resistance (MDR) against certain drugs or
cocktails, ultimately reducing their efficiency (Ponomarenko, 2020). This is worsened in cases of
chemotherapy treatment failure, which allows cancerous cells to gain resistance to such drugs
and increases chances of CNS involvement due to continuous immunosuppression. If T-ALL
cells metastasize into the CNS, they will be out of the reach of most systemic chemotherapies
due to the tight BBB (Louveau, 2018). Therefore, to kill these cells, physicians irradiate the CNS
of patients with ionizing radiation or inject chemotherapy directly into the CNS (methotrexate
and 5-fluorouracil can bypass the BBB due to their small size (Anderson, 2019; Denu, 2019)).
However, these drugs cause “chemobrain” (different types of cognitive impairments and
encephalopathies), seizures, and alter the brains cytokine production, which can have transient
and/or long-term implications in the overall development of the CNS (Han, 2017; Anderson,
2019; Denu, 2019). In addition, these drugs can lead to secondary malignancies. This is
particularly risky for infants because their immune systems are usually weaker than an adults,
and the quality of their entire lives is significantly affected since their CNS can be disrupted from
developing properly (Winestone, 2019).
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Radiotherapy uses ionizing radiation targeted to specific tissues/tumors of a patient
(PTCLs and/or PCNSLs), so this option is not well suited for circulating T-ALL cells. Wholebrain radiotherapy produced good initial response, but also high numbers of relapses (~48%) and
around 15-29% of patients experienced neurotoxic side-effects (Milgrom, 2014; Han, 2017;
Kinslow, 2020). Relapse of tumors occurred over the irradiated area and the intensity of the
radiation doses would determine the onset and intensity of the neurocognitive side-effects
(Milgrom, 2014). Radiotherapy is no longer used on its own, but instead it is added as
consolidation treatment after chemotherapy, which increased the median survival time of patients
with PCNSL to 36-60 months (Milgrom, 2014; Han, 2017).
Surgical resection is another treatment against cells that metastasize and become tumors
in other tissues/organs, but it is limited by the location of the tumor since some tissues/organs
cannot be readily resected due to their physiological importance. This caveat makes surgery
more suitable for non-CNS lymphomas, although it is not the standard therapy for lymphomas
(Kinslow, 2020; Rae, 2019). Surgery is overall associated with increased survival, but it is
reserved to relieve severe pressure, and its best results are seen when accompanied with
chemotherapy (Rae, 2019).
Improvements in these therapeutic options continue to increase the survival rates of
patients with T-ALL, but each treatment still must be used with careful consideration of its side
effects and efficiency. Regardless, these options are directed towards treating the symptoms of
advanced T-ALL, and there is currently no treatment to address the causes that influence the
incidence of T-ALL and early progression. There are also a lack of screening services and data
collection, which prevents researchers from finding the links between risk factors and incidence
of disease, as well as from providing earlier diagnoses to the affected populations.
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SIGNIFICANCE
Increasing our knowledge about the etiology of T-ALL could help in developing
treatment directed at the dysregulated cellular mechanisms and possibly make treatments
available for earlier stages of disease. By understanding the effects of the signals in these
cancerous cells, and their microenvironments, we will be able to identify safe therapeutic targets
for alternative treatments that prevent disease progression and do not provoke significant side
effects or long-term morbidities in recipients. To learn more about T-ALL progression, we can
design experiments to determine the effects of altered gene expressions in our cells of interest.
A genetic modification tool known as Clustered Regularly Interspaced Short Palindromic
Repeats (“CRISPRs”) was developed from a microbial nuclease defense system used by bacteria
to avoid infections by bacterio-phages (Hou, 2013). This mechanism has been adapted for
research purposes, and it enables the recognition of specific DNA sequences in the genome of
mammalian cells for one of two purposes: introduce or inactivate a designated genes expression
in certain cells under controlled conditions. The CRISPR inactivation system works by causing a
double-strand break within the targeted coding-sequence of cellular DNA, which if the cell fails
to repair properly, will render the gene inactive and its expression is disrupted or “Knocked-Out”
(Shalem, 2014). The modified cell line can then be used in experiments to determine how it
functions in contrast to parental cells. These studies provide information on the function and/or
effects of specific substrates in cells and their microenvironment, which help us understand how
they trigger other downstream effectors along a particular signaling cascade for disease
progression models.
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Figure 8. CRISPR-directed K.O. mechanism for protein inhibition (Ebner, 2019)

In this study, the genes for GRK-5, and 6 were individually CRISPR-targeted to
inactivate them in both CEM and in Hut-78 Human T-cell lines. This will demonstrate the effects
that each kinase has on the ligand-mediated internalization and CCR7-directed migration signals
in T-ALL cells. We expect these experiments will reveal potential of GRK-5 and/or GRK-6 as
possible therapeutic targets in the treatment of T-ALL disease progression.

22

GOALS & OBJECTIVES
1. List current T-ALL epidemiological rates and risk factors associated to the Hispanic
population in El Paso.

2. Increase our understanding of T-ALL, specifically the internalization and metastatic
properties mediated by CCR7 that is regulated by the GRK subfamily 4 members (GRK5 and 6) in CEM and Hut-78 T-ALL cell lines.

HYPOTHESIS
Disruption of one or more of the GRK subfamily 4 members (GRK-5 and 6) will
decrease CCR7-directed migration and receptor internalization in human CEM and Hut-78 TALL cells when stimulated with CCL19 and/or CCL21.
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CHAPTER 2: METHODS
Cell Culture
CEM and Hut-78 cells were cultured in RPMI 1640 media (Sigma-Aldrich, MDL#:
R8758-500ML) supplemented with 10% heat inactivated Fetal Bovine Serum (Gibco, cat#:
16000044), and 2 mM L-Glutamine (Corning, prod. #: 25-005-CV). HEK-293T cells were
cultured in High glucose DMEM media (Sigma-Aldrich, SKU: D6429-500ML) supplemented
with 10% heat inactivated Fetal Bovine Serum, and 2 mM L-Glutamine (complete media). Cells
were passaged every 2-3 days by either transferring to a centrifuge tube or trypsinization (0.25 %
Trypsin/EDTA) centrifuging at 90 x g and adding new media to a new 25cm2 flask. All cells
were kept in an incubator at 37˚C and 5% CO2 before experiments.

Flow Cytometry
150,000 CEM and HuT-78 cells were isolated for each experiment by pelleting them in a
flow cytometry tube through centrifugation at 1200 RPM and room temperature. Each pellet was
resuspended with 100 µl of PBS with 5% BSA and 2ul of each particular antibody (PE-Cy7 Rat
anti-Human CD197 (CCR7), cat. #: AB_396765, or PE-Cy7 Rat IgG2a k isotype control, cat. #:
552784, from BD Biosciences Pharmingen), there was also an untreated negative control sample.
The cells were incubated at room temperature for 1 hour and then 400 µl of complete RPMI
media were added to each flow cytometry tube before analyzing in a Beckman Coulter Gallios
flow cytometer (Beckman Coulter Life Sciences).

GRK-5 and -6 pLentiCRISPRv2 plasmids preparation
A variation of the protocol from Shalem, Sanjana, et al., Science (2014) was used to

synthesize the LentiCRISPRv2 vectors. First, 2.5µg of the stock lentiCRISPRv2 vector DNA
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(Addgene, plasmid#: 52961) were digested with 3µL of BsmBI enzyme (New England Biolabs),
in solution with 3µL DTT (100mM) (NEB), 3µL of NEB buffer 3.1 (cat#: B7203S) and 13µL of
ddH20 for a total volume of 30µL. The digestion run for 45 minutes at 55 ˚C. Then the product
was loaded into a 0.5% agarose gel (50mL Tris-Acetate-EDTA buffer, 0.5g agarose (Lonza,
cat#: 50004), and 300µL ethidium bromide at 1:10,000 (Sigma, cat#: E7637-5G) that run for 70
minutes at 105V in a gel electrophoresis chamber. The gel was cut and the DNA bands were
extracted following the protocol from the QIAEX II Gel Extraction Kit (QIAGEN, cat#: 20021).
2 different pairs of 20-nucleotide gRNA templates were designed according to the
manufacturers protocol (Shalem, Sanjana, et al., Science, 2014). These were ligated into the
digested/extracted CRISPRv2 vector to attempt each gene disruption. The forward-reverse GRK5 oligo pairs were:
GRK-5 F1: 5’ CACCGTCAACATACGCTACTTAGAC 3’,
GRK-5 R1: 5’ AAACGTCTAAGTAGCGTATGTTGAC 3’.
GRK-5 F2: 5’ CACCGGGAGTGTTACATTCAGTTCC 3’,
GRK-5 R2: 5’ AAACGGAACTGAATGTAACACTCCC 3’.
The forward-reverse oligo pairs for the GRK-6 gene were:
GRK-6 F1: 5’ CACCGGCAAAGGCAAAAGCAAGAAA 3’
GRK-6 R1: 5’ AAACTTTCTTGCTTTTGCCTTTGCC 3’.
GRK-6 F2: 5’ CACCGGACGAACTGCACCCAGCGGC 3’
GRK-6 R2: 5’ AAACGCCGCTGGGTGCAGTTCGTCC 3’.
Each individual oligo was resuspended to a final concentration of 100 µM with ddH2O and a few
variations were done to the annealing and phosphorylation steps of the protocol. 50 µL of each
oligo pair (forward and reverse) were placed in a PCR tube and heated up to 95˚C for 5 minutes,
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then the temperature was decreased by 5˚C every minute until reaching 25˚C. 6 µL of this oligo
duplex were placed in a PCR tube with 1 µL T4 ligation buffer (NEB, cat#: B0202S), 2 µL
ddH2O, and 1 µL of T4 PNK enzyme (NEB, cat#: M0201S). The reaction ran for 30 minutes at
37˚C and raised to 65 ˚C for 15 minutes, and diluted 1:100 with sterile water. A ligation reaction
for the vector and oligos was set with 1 µL of the 1:100 annealed oligo duplex, 5 µL of 2x Quick
ligation buffer (NEB, cat. #: M2200), 3µL ddH2O, 1 µL of the digested CRISPRv2 DNA (~50
ng), and 1 µL Quick ligase enzyme (NEB, cat. #: M2200). This reaction was incubated for 2
hours at room temperature.
The final product was then transformed into E. coli bacteria for vector amplification. A
tube of Stbl3 strain bacteria (Thermo Fisher, cat#: C737303) was thawed and then 9 µL of the
ligation product (~40 ng of DNA) was added to the tube and incubated on ice for 15 minutes.
The bacteria were heat-shocked in a 42˚C water bath for 45 seconds and placed back on ice for 2
minutes. 300 µL of prewarmed LB media (Invitrogen, cat. #: 22-700-041) was added to the
Stbl3 bacteria tube and placed in a shaker at 37˚C (200 RPM) for 1 hour. 200 µL of the sample
were plated on an LB media-agar plate and incubated overnight at 37˚C. The bacterial colonies
were harvested for the plasmid DNA of the CRISPRv2 vector with the ligated oligos specific to
each GRK. This was done with the QIAprep Spin Miniprep Kit (QIAGEN, cat. #27104)
following the manufacturers protocol. The plasmids were then sequenced with an LKO1
(Addgene) primer to verify our insert.

GRK-5 and -6 pLentiCRISPRv2 Lentivirus preparation
6x105 HEK-293T cells were seeded in a 6-well plate with 2 mL/well of complete DMEM
media in different plates (one for each GRK); these were incubated overnight to reach ~80-90 %
confluency. The cell media was changed 1 hour prior to transfection with fresh complete DMEM
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media. LipoD293 (SignaGen Laboratories, cat. #: SL100668) was used with a few variations to
their protocol. The plasmids used were pVSVG (gift from Josh Sanes’ lab, Harvard University),
Δ8.9 (gift from Josh Sanes’ lab, Harvard University), and each of the previously synthesized
CRISPRv2 plasmids with the specific ligated oligo for the GRK-4 subfamily genes (CRISPRv2GRK-5, and CRISPRv2-GRK-6). The ratio of plasmids was 2 µg pVSVG to 3 µg Δ 8.9 to 3 µg
CRISPRv2-GRK. 2 µg of pVSVG, 3 µg of Δ8.9, and 3 µg of either one of the CRISPRv2-GRK
plasmids (8 µg total DNA per co-transfection) were lipofected at a ratio of 3 µL lipoD293
reagent to 1 µg plasmid DNA (24 µL: 8 µg DNA total) into each HEK-293T cell plate. 300 µL
of serum-free DMEM was mixed with 24 µL of LipoD293 reagent in a 1.5 mL Eppendorf tube,
vortexed and left to incubate at room temperature for 5 minutes. 300 µL of serum-free DMEM
was added to 8µg of DNA plasmids in a 1.5ml Eppendorf tube and allowed to stand at room
temperature for 5 minutes. Then the media-LipoD293 tube was added to the media-DNA tube,
and this was left to incubate for 10 minutes at room temperature. 100µL of the final LipoD293:
DNA solution were added to each well of the 6-well plate for each separate plate. The solution
was left to incubate on the cell for 5 hours and then replaced with complete DMEM media.
The lentivirus was harvested from the supernatant media from each 6-well plate. 12 mL
total were collected from each plate and they were centrifuged at 800xg for 10 minutes along
with 4 mL of Lenti-X Concentrator solution (Takara, cat. #: 631232) at room temperature in a 50
mL conical tube. All tubes were then placed on a rocker at 60 RPM in a 4˚C refrigerator
overnight. Then the tubes were spun at 1600xg for 60 minutes at 4˚C. Each tube was decanted
without disturbing the pellet that formed at the bottom of the tubes. This pellet was gently
resuspended in 600 µL of DPBS (Corning, cat. #: 20-030-CV) and stored at -80˚C until used.
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GRK-5 and -6 pLentiCRISPRv2 Lentivirus transductions
5x105 cells of each cell line (CEM or Hut-78) were isolated in a volume of 200 µL of
RPMI media and spinoculated with a lentivirus specific for GRK-5 or -6 in a tabletop centrifuge.
The 200 µL of cells/media were placed in a 1.5ml microfuge tube along with 300 µL of the
previously synthesized CRISPRv2-GRK lentivirus for a total volume of 500 µL per tube. These
tubes were centrifuged at 2300 RPM for 2 hours at room temperature in a table-top centrifuge.
Then the tubes were incubated in a 37˚C, 5% CO2 incubator for 2 hours. Each tube was passed to
a well of a 12 well-plate and 500 µL of additional media were added into each well for a total of
1000 µL per well, the plate was incubated overnight at 37˚C, 5% CO2.

CaPO4 LentiCRISPRv2 Lentivirus preparation
Calcium Phosphate (CaPO4) transfections were done as previously described in (Llano,
2009). Briefly, 3x106 HEK-293 cells were seeded with 12ml of complete DMEM media in a 75
cm2 flask. Cells were cultured until 60-70% confluency was reached and then the following
plasmids were prepared to be co-transfected: 5 µg of pVSVG, 15 µg of Δ8.9, and 15 µg of
CRISPRv2-GRK-5 and -6. The plasmids were added to .1x TE buffer (QIAGEN, cat. #: 20021),
2.5 M Calcium Chloride, and 2x HEPES-Buffered saline (Sigma-Aldrich) in an Eppendorf tube,
this was vortexed and left to incubate for 15 minutes at room temperature. The 75 cm2 flask was
placed up-right, leaving the cell monolayer standing vertically and the media sitting at the
bottom of the flask. The DNA/transfection complex was added to the media at the bottom, and
the flask was gently placed horizontally again with the media covering the cell monolayer. The
flask was left to incubate for 24 hours, and then the media was changed for 12ml of complete
DMEM. After another 48 hours, the lentivirus was concentrated from the supernatant media
through ultracentrifugation as follows. The ultracentrifugation tubes were decontaminated with
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70% ethanol for 10 minutes and left to dry prior to centrifugation. The supernatant from the 75
cm2 flask was centrifuged in a 50 mL tube at 1200 rpm for 10 minutes and then filtered through a
0.45 µm filter bottle (Thermo Scientific, cat. #: EW-06730-34). Once the ultracentrifugation
tubes were dry, 1 mL of a 20% sucrose cushion was placed in the bottom of the tubes for every 9
mL of viral media. The viral media was gently added on top of the sucrose cushion by tilting the
ultracentrifuge tube and preventing the two liquids layers from combining. The tubes were then
placed in the ultracentrifuge rotor (Thermo Scientific, cat. #: F13-14x50cy) and capped carefully.
These tubes were centrifuged at 26,500 rpm for 2 hours at 4 ˚C (Thermo Scientific, Sorvall RC 6
Plus). After spinning, all the supernatant was carefully removed by aspiration without disturbing
the pellet at the bottom of the tubes. 200 µL of RPMI media were placed on top of the pellet and
this was incubated on ice for 15 minutes. The pellet was gently resuspended to avoid bubbles and
aliquoted into cryotubes which were stored at -80 ˚C until used.

Western Blot
Sodium dodecyl sulfate-Poly Acrylamide Gel Electrophoresis (SDS-PAGE) and Western
blotting were done as previously described in (Cheng, 2008). Briefly, whole cell lysates were
prepared with 1, 2, or 3 x106 cells in 1 mL lysis buffer (10 mM Tris (Fisher Scientific, cat. #:
BP152-500), 5 mM EDTA (Sigma-Aldrich, cat. #: E9884), 50 mM Sodium chloride (Sigma), 30
mM Sodium pyrophosphate (Fisher Scientific), 50 mM Sodium fluoride (Sigma), 1 mM Sodium
ortho-vanadate (Sigma-Aldrich), and 1% Triton X-100 (Sigma-Aldrich)) and protease-inhibitors
(5µg/ml Aprotinin (Thermo Scientific), 1 μg/ml PepstatinA (Sigma-Aldrich), 2 μg/ml Leupeptin
(Thermo Scientific), and 1 mM phenylmethylsulphonyl fluoride (Thermo Scientific)) for each
cell line (CEM and Hut-78). These were quantified using a BCA assay and normalized to 2
µg/µL with sample buffer (20 % Glycerol (Sigma), 10 % 2-mercaptoethanol (Sigma-Aldrich),
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4.6 % SDS (Bio Rad), 0.125 M Tris, and 0.004 % Bromophenol blue (MidSci)). Samples were
boiled at 95 ˚C for 5 minutes before loading 30 µg of each lysate into a well of an 10%
acrylamide SDS-PAGE gel. The gels ran for 3 hours at 100 volts in an electrophoresis chamber
filled with running buffer. The proteins in the gel were then transferred to a PVDF membrane
(pre-wetted with 100% methanol for 30 seconds) for 1 hour and 20 minutes at constant 195
mAmps using a semi-wet Electrophoresis Power Supply (Amersham Bioscience, EPS 301) in
transfer buffer. The membranes were blocked with 3 % BSA (MP Biomedicals, cat. #:
MP219989825) in TBS-T buffer (0.2 M Tris base (Sigma-Aldrich, cat. #: TRIS-RO), 1.37 M
NaCL, and 0.25% Tween 20 (Sigma-Aldrich, cat. #: P9416)) overnight at 4 ˚C, and then washed
three times with TBS-T before probing with antibodies for GRK-6 (Santa Cruz Biotechnology,
cat. #: sc377494) or β-actin (Cell Signaling Technology, cat. #: 4967) at a concentration of
1:1000 in 3% BSA in TBS-T for 5 hours at 4 ˚C. A secondary antibody (Invitrogen, Goat antimouse (cat. #: 31430) and Goat anti-rabbit (cat. #: 31460)) for each primary antibody was
incubated on each membrane for 40 minutes at room temperature at a concentration of 1:10,000
in TBS-T, and then the Super Signal West Pico Substrate (Pierce, Thermo Scientific, cat. #:
34577) was added before developing the membrane image in an iBright Imaging System
(Thermo Fisher). Results from the western blots were then quantified for densitometry tests with
the Thermo Fisher Scientific iBright IBA online platform.

GRK-5, and -6 Double-Nickase plasmid transfection
A pair of pre-made CRISPR-Cas9 plasmids specific for GRK-5 (cat. #: sc-401285-NIC),
and -6 (cat. #: sc-402061-NIC) were ordered from Santa Cruz Biotechnology. Cell viability was
checked prior to running experiments by adding Propidium Iodide (PI, Invitrogen, cat. #:
P1304MP) to the cells and running them in a flow cytometer to detect PI uptake. Then the
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double-Nickase plasmids were transfected into CEM and HuT-78 cells through nucleoporation
with the Lonza/Amaxa Nucleofector 2B (Lonza, cat. #: AAB-1001). 4 µg of total combined
plasmid DNA or GFP control (Lonza, #: VCA-1003) were required for each experiment with 2
million cells per sample. Cells were centrifuged at 200xg for 5 minutes and all supernatant media
was removed, then the cell pellet was resuspended with 100 µL of Gibco Opti-MEM I ReducedSerum Medium (Fisher Scientific, cat. #31-985-062), and the plasmid DNA or GFP was added.
The cells were transferred to an aluminum nucleofection cuvette (Lonza, #: VCA-1003) and the
program X-001 or U-014 were executed. After the program ended, 500 µL of prewarmed
complete RPMI media were used to transfer the cells to a prewarmed 12-well plate with 2 mL of
media. Media was changed 6 hours post-transfection and GFP control expression was checked
after 24 hours.

pCDH-EF1-Luc2-P2A-tdTomato control Lentivirus
12 x106 HEK293 cells were seeded in a 150 mm plate with 35 ml of complete DMEM
media and cultured until 60-70% confluence was acquired. The media was changed for 25 mL of
fresh complete DMEM 4 hours before transfection, and the following plasmids were prepared in
1 mL of serum-free media: 2 µg of pVSVG, 8 µg of Δ8.9, and 16 µg of pCDH-EF1-Luc2-P2AtdTomato (Addgene, plasmid # 72486), which was vortexed and incubated at room temperature
for 5 minutes. On a separate tube, 78 µL of LipoD293 transfection reagent were added to 1ml of
serum-free media, which was vortexed and incubated for 5 minutes at room temperature. The
transfection reagent/media was then added to the DNA/media, this was vortexed, and incubates
for 15 minutes at room temperature. The DNA/transfection reagent complex was then added
dropwise into the 150 mm plate trying to cover all the surface of the plate. After 18 hours, the
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media was changed with 25 ml of complete DMEM, and the cells were left to incubate for 48
more hours. The media from the plate was then aspirated gently and centrifuged at 500xg for 5
minutes to remove cell debris. This media was then passed through a 0.45 µm filter bottle and
placed in a clean 50 mL conical tube. 8 mL of Lenti-X Concentrator solution were added to the
filtered media and was left to incubate for 1 hour at 4˚C. The tube was then centrifuged at
1500xg for 1 hour at 4˚C and a pellet formed at the bottom of the tube. The supernatant was
carefully decanted, and the pellet was resuspended with 1.6 mL of complete DMEM, these were
aliquoted into smaller volumes in individual Eppendorf tubes and frozen at -80 ˚C until used.

GRK-6 esiRNA transfection
Cell viability was checked prior to running experiments by adding PI to the cells and
running them in a flow cytometer to detect PI uptake. Then, a tube of MISSION® esiRNA
(endoribonuclease prepared siRNA heterogenous mixture of siRNA that target the same
sequence) targeting the human GRK-6 gene (Eupheria Biotech, cat. #HU-11557-1) was
resuspended in 100 µL of IDTE 1x TE solution (Integrated DNA Technologies, cat. # 11-05-0109) to a concentration of 500 ng/µL. One, two, and three million cells (CEM or HuT-78) were
isolated by centrifugation at 90xg for 5 minutes. All supernatant media was removed, and then
the cell pellets were resuspended with 100 µL of Gibco Opti-MEM I Reduced-Serum Medium to
transfer the cells to an aluminum nucleofection cuvette (Lonza). 1 µg of esiRNA was added to
the cuvettes for every million cells of each sample, and the program X-001 was executed in the
Lonza/Amaxa Nucleofector 2B. After the program ended, 500 µL of prewarmed complete RPMI
media were used to transfer the cells from the cuvette to a prewarmed 6-well plate with 2 mL of
complete RPMI media. 1 mL of complete RPMI media was added 24 hours post-transfection to
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each sample, and the cells were collected at 48- and 72- hours port-transfection to run further
experiments.
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CHAPTER 3: TIMELINE
This thesis project was carried out from the Fall 2017 semester to the Fall 2021 semester.
Prior to this, several trainings and prerequisites for research were completed near the end of
Spring 2017. Fall 2017 and Spring 2018 were mostly dedicated to researching literature and
getting familiar with the techniques and protocols necessary for the setup of the experiments.
The oral proposal was completed during Fall 2018, and the written component was submitted
and accepted at the end of Spring 2022.
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CHAPTER 4: RESULTS AND DISCUSSION
RESULTS
Hispanic T-ALL rates from various Health Agencies:
Leukemia rates per 100,000 individuals
Agency
Incidence
Death rates
Survivors/Survival Rate
The National Cancer Institute - 2013-2017: Hisp. 2014-2018: Hisp.
*National level
F: (10); M: (14.3) F: (3.6); M: (5.6)
The Healthy Paso del Norte
Foundation (2022) - Local
level
The Texas Cancer Registry
(HHS estimates) - State level
Healthy People 2020 National level
Healthy People 2030 National Level
SEER - **Regional Level

-

-

2021: F: (1849)
2021: F: (748)
2.9% ; M: (2550) 3.5%; M: (1,105)
3.8%
4.4

-

2018 survirors: F:
(12,444); M: (16,158)

-

-

-

-

-

-

2014-2018: Hisp. 2014-2018: Hisp.
F: (2.2); M: (2.9) F: (.6); M: (.8)

2011-2017 Rate: 69.9%

Figure 9. Hispanic local, state, and national rates associated with T-ALL from different health agencies. (*): Areas
in the US with "High" quality incidence data. (-): No data available. (**): SEER includes data on 9 specific
states/regions of the country. (Cancer data have been provided by the Texas Cancer Registry, Cancer Epidemiology
and Surveillance Branch, Texas Department of State Health Services, 1100 West 49th Street, Austin, TX 78756;
Islami, 2021).

The Healthy Paso del Norte Foundation, The Healthy People 2020, and Healthy People
2030 organizations do not have any rate or objectives related to Leukemia (Healthy Paso del
Norte; Healthy People 2020, 2021; Healthy People 2030, 2021). The National Cancer Institute
reports that in 2019, El Paso had 32.8 % of their population younger than 65 years of age with no
insurance. This agency has several data reports, but they mention that their data is only about the
areas in the country with “high quality” data, and their latest T-ALL rates go up to the year 2018.
The Texas cancer registry reports that Hispanics in El Paso County have a crude incidence rate
of 2.5 cases per 100,000 individuals, while non-Hispanic Whites have a rate of 1.9 cases per
100,000 individuals (data from 1995 to 2018). SEER currently reports the data of 9 specific
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regions in the US (Texas not included), and they report those Hispanic males have a rate of 2.9
new cases per 100,000 individuals and females had 2.2 (from 2014 to 2018), which was higher
than the rate for non-Hispanic White males (2.2) and females (1.7). They also report that 53.5%
of all new cases were seen in the <20 years of age group, and mortality is higher in both male
and female Hispanics (0.8 and 0.6 per 100,000 individuals respectively) when compared to nonHispanic White males and females (0.6 and 0.4 respectively). The 5-year relative survival rate
for people with T-ALL was 69.9% (data from 2011 to 2017; National Cancer Institute, SEER,
2022).
Many of these data sources report different rates for different time periods, which may be
due to the area of data collection, organizational requirements for data collection and cancer
reporting, lack of insurance, and the populations willingness and/or inability to participate in
cancer screening programs. Risk factors for T-ALL are not detailed by these organizations, and
there is no information about possible connections between exposure factors and incidence to
make the population aware of this condition.

Flow cytometry
To examine the levels of CCR7 expressed in our T-ALL cell lines, we used flow
cytometry. CEM and HuT-78 cells were probed with an antibody against CCR7 to detect the
presence of the receptor in the cell membranes. Results show that both cell lines express CCR7
on their membranes.
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Figure 10. Flow cytometry of CEM cells membrane to detect CCR7 (blue and orange peaks), isotype control (green
peak), and untreated cells (red peak).

Figure 11. Flow cytometry of Hut-78 cells membrane to detect CCR7 (blue and orange peaks), isotype control
(green peak), and untreated cells (red peak).

pLenti-CRISPRv2-Cas9 GRK-5 and -6 preparation
The lentiCRISPR v2 vector plasmid was digested and extracted to anneal our guide-RNA
sequences for GRK-5 and -6. The plasmid was then sequenced to verify the presence of the
guide-RNAs (shown below in bold).
>GRK-5 gRNA in pLenti-CRISPR v2 vector, clone 4
CWMRWKAWTTYCRATTTCTTGGCTTTATATATCTTGTGGAAGGACGAAACACCGT
CAACATACGCTACTTAGACGTTTTARAGCTAGAAATAGCAAGTTAAAATAAGGCTA
GTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTGAATTCGCTAGC
TAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCAC
ATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGATCCGGTGCCT
37

AGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTT
TTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTT
TTTCGCAACGGGTTTGCCGCCAGAACACAGGACCGGTTCTAGAGCGCTGCCACCATG
GACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGT
GATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCG
ACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAA
ACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGA
AGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGAC
GACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCA
CGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGT
ACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGAC
CTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTTCCT
GATCGAGGGCGACCTGAACCCCGACAMCAGCGACGTGGACAAGCTGTTCMATCCA
GCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAAACCCCCATCAACGCCAGCGG
CGTTGAMSGCCAAGGCCATTCTGTCTGCCAGACTTGAGCAAGAAGYCAGACGCTTG
AAAATCTGAATCCGCCCAGCTGCCGCGAGAAGAAAGAAATGGACCTKATTCSGAAC
>GRK-5 gRNA in pLenti-CRISPR v2 vector, clone 5
AAWTTYYGATTTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGTCAAC
ATACGCTACTTAGACSYTTTWRAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCC
GTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTGAATTCGCTAGCTAGG
TCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCG
CCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGATCCGGTGCCTAGAG
AAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCC
CGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCG
CAACGGGTTTGCCGCCAGAACACAGGACCGGTTCTAGAGCGCTGCCACCATGGACA
AGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATC
ACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCG
GCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAG
CCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAA
CCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACA
GCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAG
CGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCC
CACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGC
GGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCG
AGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTG
CARACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGC
CAAGCCATTCTGTCTGCAGACTGAGCAGAAGCAGACGGCTGGAAAATYCTGAATCG
TCTAGCTGCCGTCAGAAGAGAATGGACTGATTCGAAACCTGAATTGKTCT
>GRK-6 gRNA in pLenti-CRISPR v2 vector, clone 3
TATTTYCSATTYTTGGCTTTATATATCTTGTGGAAGGACGAAACACCGGCAAAGGC
AAAAGCAAGAAASTTTTWRAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTT
ATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTGAATTCGCTAGCTAGGTCT
TGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC
ACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGATCCGGTGCCTAGAGAAG
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GTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGA
GGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
CGGGTTTGCCGCCAGAACACAGGACCGGTTCTAGAGCGCTGCCMCCATGGACAAGA
AAGTACAGCATCGGSCCTGGAMMATCGGCACCMAMYTCTGTGGGCTGGGCCGKGA
TYMMCCGAMGAAGTMCAAGGTGSCCCAGCMAGAAAATTYMARGGGGCTGGGSMA
CAMCCGAMCCGGMMMRCATCAAGAAARAACCTKGATCSGAASCCCGSYTGTTSAM
MAGCGGSGAAACASCCAAGCCMCCCGGYKAAAGAAMCCCCGAAGAARAAWCCCC
AAMSGAARAMCCGRTTTGSTTYTGMAAAWTYTYMAMACAAATGGSCARGKGGRMR
AAARYTTTCTCCMRAWKGGARAAKCYTCCTGKGARAGAKAAAASCRARGGRCCCW
TTTSGAAWYGGAMARAGGSCMCCGRAARCCCCCCCCTCCACCCYRAAAAMYGGKA
SACCMAMRGCRACSGGKKATTYGKCTKGMACAKARAATWCSGKCTTTSTRAAWGM
GMCWAACCATACASCGRGAGKAGSGTSTATACACTSTTGTGCTYATCACTAKTGTSA
GAACACTAWCAWAYSMGGGGGTGATKAACGCRCSASYTCTCC
>GRK-6 gRNA in pLenti-CRISPR v2 vector, clone 6
AAAWTTYYGAATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGCAA
AGGCAAAAGCAAGAAAGTTTTWKAGCTAGAAATAGCAAGTTAAAATAAGGCTAGT
CCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTGAATTCGCTAGCTA
GGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACAT
CGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGATCCGGTGCCTAG
AGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTT
CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTT
CGCAACGGGTTTGCCGCCAGAACACAGGACCGGTTCTAGAGCGCTGCCACCATGGA
CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA
TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC
CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC
AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG
AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA
CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG
AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC
CCCACCATCTACCACCTGAGAAAGAAAACTGGTGGACAGCACCGACAAGGCCGACC
TGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGA
TCGAAGGCGACCTGAACCCCGACAACAGCGACGTGGACAGCTGTTCATCCAGCTGG
TGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGACG
CCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAATCTGATCG
CCCAGCCTGCCGGGCGARAAGAAGATGGCCTGATCGGAAACTKGAATTKGCCTGTG
RAGCCCATG
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GRK-5 and -6 pLentiCRISPRv2 Lentivirus
After constructing the CRISPR plasmids that target each protein of interest, a lentivirus
was synthesized to inoculate CEM and HuT-78 cells. A western blot was used to see if the
amount of protein expressed had been successfully reduced in the cells.
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Figure 12. Western blot of CEM and HuT-78 cells after inoculation with each separate CRISPR lentivirus and
probed with an GRK-4-6 antibody (65-70 kDa). Sample order from left to right: (a: control CEM, b: CRISPR GRK4 CEM, c: CRISPR GRK-5 CEM, d: CRISPR GRK-6 CEM, e: control HuT-78, f: CRISPR GRK-4 HuT-78, g:
CRISPR GRK-5 HuT-78, h: CRISPR GRK-6 HuT-78).
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Figure 13. Western blot of CEM (control, CRISPR GRK-4, -5, and -6) and HuT-78 (control, CRISPR GRK-4, -5,
and -6) cells after inoculation with each separate GRK-CRISPR lentivirus and probed with a GRK-5 antibody (68
kDa). Sample order from left to right: (a: control CEM, b: CRISPR GRK-4 CEM, c: CRISPR GRK-5 CEM, d:
CRISPR GRK-6 CEM, e: control HuT-78, f: CRISPR GRK-4 HuT-78, g: CRISPR GRK-5 HuT-78, h: CRISPR
GRK-6 HuT-78).

Both blots seemed to have no significant difference among the different samples and
controls, except for the CEM cells with the GRK-6 CRISPR (column “d”). This lentivirus was
then synthesized with the CaPO4 procedure, which we thought would increase efficiency of the
lentivirus.
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CaPO4 LentiCRISPRv2 Lentivirus
This was the second approach to try to inhibit GRK-6 after seeing that the previous
CRISPR-GRK-6 lentivirus may have reduced GRK-6 on CEM cells. The GRK-6 CRISPR was
retried with this protocol to inoculate CEM cells to repeat the results from the previous western
blots.
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Figure 14. Western blot of CEM control cells and CEM-CRISPR-GRK-6 treated cells with a GRK-6 antibody probe
(66 kDa). Sample order from left to right: (L: ladder, a: control CEM, b: CRISPR GRK-6 CEM).

The new western blot of the new lentivirus protocol showed that there was no difference
in the expression of GRK-6 in treated cells when compared to the controls, so we looked for an
alternative method. Future studies would require a control house-keeping antibody to verify
equal loading, and then normalize and quantify the expression of GRK-6.
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GRK-5, and -6 Double-Nickase plasmid transfection
Cell viability was high for untreated HuT-78 cells as indicated by the low uptake of PI
checked with a flow cytometer before nucleofecting with the Double-Nickase plasmids. We
observed between 94 and 99.4% viability prior to nucleofection.

Figure 15. A) Non-treated HuT-78 cells without PI observed in a flow cytometer before nucleofection (99.40 % live
cells). B) Non-treated HuT-78 cells with PI observed in a flow cytometer before nucleofection (94.04 % live cells).

Figure 16. HuT-78 cells 72-hours after nucleofection (no DNA plasmid added), observed in a flow-cytometer (18.99
% live cells).
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Figure 17. A) HuT-78 cells 72 hours after nucleofection (2 g of DNA plasmid were added to 1 million cells),
observed in a flow-cytometer (41.90 % live cells). B) HuT-78 cells 72 hours after nucleofection (4 g of DNA
plasmid were added to 1 million cells), observed in a flow-cytometer (56.51 % live cells).

We observed that the cell viability was significantly decreased (high uptake of PI) by the
nucleofection process since there was a large percentage of cell death, regardless of the addition
of DNA plasmids. The cells were then observed under a microscope for fluorescence.

Figure 18. Non-nucleofected HuT-78 control cells viewed under a light microscope 10x.
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Figure 19. One million HuT-78 cells 72 hours after nucleofection with 4 g of GFP plasmid viewed under a light
microscope (10x).

Figure 20. One million HuT-78 cells 72 hours after nucleofection with 2 g of GFP plasmid viewed under a light
microscope (10x).

The cells expressing green fluorescence indicate a functional GFP plasmid occurred in a
low percentage of HuT-78 cells, indicating a low efficiency of nucleofection, although as shown
above, many of the cells will have died because of nucleofection alone. Cell death via
nucleofection was greater in CEM cells, as was the percentage of green fluorescent cells (data
not shown).
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pCDH-EF1-Luc2-P2A-tdTomato control lentivirus
A control lentivirus was synthesized with a red fluorescent protein to verify the efficiency
of transduction of our lentiviruses in CEM cells.

Figure 21. CEM cells inoculated with 100 L of pCDH-EF1-Luc2-P2A-tdTomato lentivirus, seen after 72 hours
post inoculation viewed under a light microscope at 20x.

Figure 22. CEM cells inoculated with 400 L of pCDH-EF1-Luc2-P2A-tdTomato lentivirus, seen after 72 hours
post inoculation viewed under a light microscope at 20x.

Results show that the intensity of the fluorescence increased as the level of lentiviral
expression increased; however, the fluorescence seems to be localized to vesicles within cells
rather than illuminating the whole cell as with the Double-Nickase plasmids method. At this
point, none of our procedures were working, so we tried a new approach to reduce the GRK
expression.
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GRK-6 esiRNA transfection
Before nucleofecting CEM and HuT-78 cells with the GRK-6 esiRNA, viability was
checked on a flow cytometer using PI. Experiments were performed when initial viability was
above 90%.

Figure 23. A) CEM cells without PI before nucleofection (99.56 % live cells). B) CEM with PI before nucleofection
(97.43 % live cells).

Figure 24. A) HuT-78 cells without PI before nucleofection (99.69 % live cells). B) HuT-78 with PI before
nucleofection (93.13 % live cells).
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Viability was checked again 48 hours after nucleofection in a flow cytometer.

Figure 25. A) CEM control cells (2 million) 48 hours post nucleofection without esiRNA (6.92 % live cells). B)
HuT-78 control cells (2 million) 48 hours post nucleofection without esiRNA (72.62 % live cells).

Figure 26. A) 1 million CEM cells 48 hours post nucleofection using 1 g esiRNA (4.33 % live cells). B) 1 million
HuT-78 cells 48 hours post nucleofection using 1 g esiRNA (58.73 % live cells).
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Figure 27. A) 2 million CEM cells 48 hours post nucleofection using 2 g esiRNA (15.26 % live cells). B) 2 million
HuT-78 cells 48 hours post nucleofection using 2 g esiRNA (32.06 % live cells).

Figure 28. A) 3 million CEM cells 48 hours post nucleofection using 3 g esiRNA (3.88 % live cells). B) 3 million
HuT-78 cells 48 hours post nucleofection using 3 g esiRNA (39.17 % live cells).

We found that the nucleofection kills significant numbers of cells in both cell lines used,
however, CEM dies at a 10-fold higher rate than Hut-78. The next steps were to collect the cell
48

samples at 48 and 72 hours after nucleofection, quantify their amounts of protein, and run a
western blot to check for GRK-6 expression. Western blots were then analyzed with Thermo
Fisher Scientific iBright IBA online platform for densitometry tests.
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Figure 29. A). Western blot of CEM cells treated with esiRNA-GRK-6 and using a GRK-6 antibody (66kDa).
Sample order from left to right: a: CEM control, b: CEM 72h 3:3, c: CEM 72h 2:2, d: CEM 72h 1:1, e: CEM
nucleop. w/o esiRNA, f: CEM 48h 3:3, g: CEM 48h 2:2, h: CEM 48h 1:1, L: ladder. B) Western blot membrane
after stripping and re-probing for β-actin (45kDa).

GRK-6 expression after esiRNA in CEM cells
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control

48 h 3:3 48 h 2:2 48 h 1:1

Figure 30. Densitometry quantification of GRK-6 expression Western blot after esiRNA nucleofection of CEM
cells. Results normalized to housekeeping gene expression. Thermo Fisher Scientific iBright IBA online platform
was used for densitometry.
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Figure 31. A). Western blot of CEM cells treated with esiRNA-GRK-6 and using a GRK-6 antibody (66kDa).
Sample order from left to right: a: CEM control, b: CEM 72h 3:3, c: CEM 72h 2:2, d: CEM nucleop. w/o esiRNA, e:
CEM 48h 3:3, f: CEM 48h 2:2, L: ladder. B) Western blot membrane after stripping and re-probing for β-actin
(45kDa).
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Figure 32. Densitometry quantification of GRK-6 expression Western blot after esiRNA nucleofection of CEM
cells. Results normalized to housekeeping gene expression. Thermo Fisher Scientific iBright IBA online platform
was used for densitometry.
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Figure 33. A). Western blot of HuT-78 cells treated with esiRNA-GRK-6 and using a GRK-6 antibody (66kDa).
Sample order from left to right: L: ladder, a: HuT-78 48h 1:1, b: HuT-78 48h 2:2, c: HuT-78 48h 3:3, d: HuT-78
nucleop. w/o esiRNA, e: HuT-78 72h 1:1, f: HuT-78 72h 2:2, g: HuT-78 72h 3:3, h: HuT-78 control. B) Western
blot membrane after stripping and re-probing for GAPDH (37kDa).
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Figure 34. Densitometry quantification of GRK-6 expression Western blot after esiRNA nucleofection of HuT-78
cells. Results normalized to housekeeping gene expression. Thermo Fisher Scientific iBright IBA online platform
was used for densitometry.
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Figure 35. A). Western blot of HuT-78 cells treated with esiRNA-GRK-6 and using a GRK-6 antibody (66kDa).
Sample order from left to right: L: ladder, a: HuT-78 48h 1:1, b: HuT-78 48h 2:2, c: HuT-78 48h 3:3, d: HuT-78
nucleop. w/o esiRNA, e: HuT-78 72h 1:1, f: HuT-78 72h 2:2, g: HuT-78 72h 3:3, h: HuT-78 control. B) Western
blot membrane after stripping and re-probing for GAPDH (37kDa).
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Figure 36. Densitometry quantification of GRK-6 expression Western blot after esiRNA nucleofection of HuT-78
cells. Results normalized to housekeeping gene expression. Thermo Fisher Scientific iBright IBA online platform
was used for densitometry.

Nucleofections of CEM and HuT-78 cells with the GRK-6 esiRNA results in a reduction
in the expression of GRK-6. Protein expression intensity was quantified using Thermo Fisher
Scientific iBright IBA online platform.
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State whether you accomplished the goal of the project; if aspects were not completed,
explain:
The local rates and epidemiological data for the city of El Paso were obtained, but they
were not as comprehensive as data about other diseases. The transductions needed for the gene
inhibition of the GRK-4 subfamily were challenging, and there are limitations to what I could do
with the nucleofections. A stable cell line with the desired modifications was not produced to test
chemotaxis changes.
Describe any obstacles that you faced in completion of the project and how you addressed
these:
Some health agencies did not provide any information about T-ALL. My CRISPR
plasmids did not reduce the expression of any GRK in the cells of interest, but a similar
lentivirus was tested as a control to get an idea of the methods efficiency. In the end, I had to use
a different approach with esiRNA to try to reduce protein expression through nucleofections.
This process was also very harsh on the cells (low cell viability after treatment), but it did show a
difference in protein expression through a western blot densitometry test.
State whether you followed all of the planned steps; state which steps were essential to the
process and what steps were not needed or not feasible, if any:
I followed most of the planned steps for the project, but there were experimental
protocols which I could not get to work after repeated troubleshooting. Researching literature,
trying new protocols, and troubleshooting them were the most essential parts to progress in this
project. The protein expression reduction was not achieved through the CRISPR system.
Summarize your experience interacting with the agency, including responses of the agency
at different stages of the project, and what contributed to development of a relationship
with the agency:
The time I spent learning in the biological sciences department taught me a lot about how
research is conducted. Troubleshooting was a great part of many experiments, but there was
always someone who could help me with new protocols. Talking to the many professors and
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their students from around the building showed me many different procedures that were useful
for this project. Researching papers and databases was also an important part of the project.
Summarize your experience of the process, including development and completion of the
project:
The learning curve for the theoretical background and most experiments was complicated
and lengthy. This project was intimidating because it was my first time doing many of the
experiments needed, and they took a considerable amount of time to master. At the end of the
project, I did feel like I got a comprehensive experience in research and public health issues.
Brief re-statement of the problem or question addressed, goal of the research, and results:
-1st question: Find the current health information related to T-ALL in the city of El Paso
and the surrounding area. The goal was to gather any available local, state, and national data, but
the results varied among agencies.
-2nd question: Will the inhibition of the GRK-4 subfamily have an effect in the migration
of T-ALL cells through the CCR7 pathway? The goal was to inhibit the GRK proteins in T-ALL
cells to run some tests afterwards and verify the function of those proteins. The results from the
CRISPR lentivirus showed no reduction in the expression of the GRKs, however a reduction of
GRK-6 expression may have been accomplished through esiRNA nucleofection.
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DISCUSSION
T-ALL is a disease that can be induced by environmental and genetic factors. Populations
that are exposed to or handle carcinogens (agricultural, industrial, manufacturing workers, etc.)
should be made aware of the potential risk and preventive practices that must be followed when
working or being exposed to these factors. An example is the widely used herbicide “Roundup”,
which contains glyphosate that has been designated “Category 2a,” which specifies probable
carcinogenic effects in humans (Singh, 2020). Health interventions and screening services for
early detection could be useful to document the actual burden of disease of T-ALL in the region,
but currently there are no local data collection efforts for this specific disease. Some data sources
point out some health disparities among different races, but these rates are misleading since their
data collection strategies and requirements may differ among agencies. T-ALL data could help
make the population aware of health risks and needs, but the implementation of an effective
intervention strategy depends on many variables (insurance, immigration status,
education/awareness, etc.), which also requires the collaboration of the affected communities.
The cellular mechanisms that initiate, maintain, and allow T-ALL to progress are very
extensive and require significant efforts to map. Sequencing the genes of these cells could be a
way of identifying other dysregulated targets, and the knowledge about their functions in T-ALL
signaling could provide a base to develop an effective therapy against its progression. In these
experiments, a sustainable cell line with the desired experimental conditions was not generated to
test my hypothesis, but GRK-6 expression may have been reduced through an alternative
transfection method. The resulting cells were significantly damaged after the process, so this
protocol will require optimization and troubleshooting to finish the chemotaxis and
internalization assays.
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GAPS IN LITERATURE
Public Health and Microbiology have their own gaps in literature about T-ALL. Public
health deals with the external causes (living conditions, risk behaviors, socioeconomics,
environment, data collection, etc.) that provoke pathogenesis and incidence of disease. There are
exposures to factors that explain the elevated rates of leukemias in several populations, including
Hispanic adults and children (Perez-Saldivar, 2008; Tsai, 2014), and the most common reasons
for these exposures are due to activities involved in the adult occupations. Industries such as
manufacturing services (machinery, oil/gas, semiconductors, mechanics, textiles, packing, and
food), office workers (bankers, insurance agents, public safety/administration, and teachers),
nursing/health care staff, mining, construction, dry cleaning, janitorial staff, and agricultural
workers can have their employees handle or exposed to: asbestos, benzene, formaldehyde,
pesticides/herbicides, fertilizers, cleaning products, cytotoxic drugs, infectious agents,
electric/magnetic fields, and ionizing radiation among others, some of which are known
leukemogens responsible for the onset of certain types of cancers (Robinson, 2015). Repeated
exposure to risk factors, misuse/mishandling of reagents, and bioaccumulation of leukemogens
could cause these factors to be brought home, which may expose more individuals (adults and
children) and possibly cause the development of hematopoietic malignancies among other health
conditions (Keegan, 2012). This increases the need for health screening services, which could
document the direct causes of pathogenesis so that the exact factors, or exposure to these factors
can be addressed to prevent further incidence of disease. Comprehensive data collection could
help us relate these exposures to physiological dysregulations, such as the genetic mutations
driving cancer progression. This data would also help link these factors to their microbiological
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outcomes, which could be achieved by updating and standardizing data registries to collect local
cancer data.
Molecular biology studies the cell signaling mechanisms, including the altered gene
expressions responsible for disease incidence, its microenvironment, and treatment to stop and
revert its progression. Cancerous cells have numerous genetic mutations and chromosomal
damage, which result in dysregulated expression of growth factors, chemokines, and receptors,
and these in turn will disrupt homeostasis, as well as cell differentiation, division, and metastatic
mechanisms (Perez/Saldivar, 2008; Bar-Shavit, 2016; Heldin, 2016). Identifying the altered
(overexpressed or suppressed) genes in T-ALL cells would be a good approach to document and
understand the etiology of the disease.
Each different type of cancerous microenvironment needs experiments to identify the
function of its pathogenic cellular pathways, from its incidence to its terminal stages. Besides the
dysregulations that cause carcinogenesis, there are many other pathological signals in these
microenvironments that influence disease progression, such as the events leading to CNS
infiltration. Some of the infiltration processes are similar for leukemic cells because some
hematological malignancies have similar mutations and undergo chemotaxis towards similar
receptors through the lymphatic and blood vessels around the CNS (Fuhrmann, 2018; Yao,
2018). These mutations allow cancerous cells (which have already infiltrated the leptomeninges)
to disorganize the tight junctions of the BBBs epithelium, letting other cells and growth factors
from the blood stream into the leptomeningeal compartments. This changes the cerebrospinal
fluid (CSF) composition so that it becomes a more suitable environment for those cells to
proliferate and possibly infiltrate the CNS of patients with leukemias, especially those without
health awareness or treatment. A GPCR involved in these processes is C3aR, which is a product
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of the complement component 3 (C3) of the complement and coagulation signaling cascade
(Boire, 2017). Another mediator of infiltration is the Phosphoinositide 3 Kinase (PI3K) which
was found to promote CNS infiltration once it was experimentally inhibited in mouse models
(Yao, 2018). These studies demonstrate that certain cell receptors and substrates are of direct
relevance to disease progression, but the specific mechanisms used by T-ALL cells need further
studies to map the most consequential signals for their treatment.

Figure 37. Infiltration of cancerous cells into leptomeninges and adaptation of the CSF composition through bloodbrain barrier disorganization (Boire, 2017).

The most common and effective treatment for leukemias is chemotherapy, which depletes
the lymphoid blast population of cells, such as those of T-ALL, but some myeloid populations of
cancerous cells seem to persist even after treatment (Gokbuget, 2011). These myeloid cells are
thought to be responsible for adapting some tumor microenvironments, which promotes the
maintenance of cancerous cells after chemotherapy, and could possibly enable disease relapse.
However, it is still not clear which genes allow these cells to resist treatment, or the specific
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genes used to sustain their microenvironments. The immune response can be activated by ~ 20
GPCRs (CXCR1, CXCR2, CXCR4, CCR5, CCR7, etc.) and ~ 40 chemokines that are induced
by inflammatory stimuli, and requires precise expression to signal cell traffic in the lymphatic
system for an appropriate immune response (Jaeger, 2019). This suggests many possible targets
for therapy that can be addressed in the signaling microenvironment. GRK-5 and GRK-6 are
expressed in all human cells, and GRK-6 is highly expressed in immune cells. However, the
function of these GRKs is still unclear for some cells, because inhibiting GRK-6 can lead to a
reduction in CXCR4-mediated chemotaxis of T-cells, but an increase in chemotaxis with this
same receptor in neutrophils (Fong, 2002; Lefkowitz, 2008; Yuan, 2013). This indicates that
certain hematological malignancies may require cell specific therapies and understanding these
signals could help us identify possible targets.
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Describe how the agency will use the results of your report and describe other possible
applications of the findings
The agency might not have a direct use for these results, but they may be used to get a
broader view of the data collection status in the region, state, and country. Plenty of background
information was gathered about possible causes of the disease, as well as some related effectors
of this signaling pathway. Experimentally, we did find a possible way of reducing certain
proteins expression with esiRNA in T-ALL cells.
Implications of findings for public health
Data collection about T-ALL shows the need for public health interventions. The results
of the experiments could provide possible therapeutics for Human T-ALL. These could also be
used to link these types of genetic dysregulations to possible environmental or occupational
factors observed in the Hispanic populations of the border region.
Explain what changes you would make to the project process if you were asked to do the
same type of project in the future
The changes for a future project would be to verify the efficiency of the CRISPR-guide
DNA sequences used for gene inactivation lentiviruses, as well as sequencing a specific cell line
and identifying any genetic alterations which could be used as targets for therapy. After seeing
that esiRNA was more viable than lentiviruses and DNA plasmids to reduce protein expression
in T-ALL cells, I would recommend optimizing this approach to try and inactivate GRK-5 and -6
to do further tests.
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CONCLUSION
T-ALL data collection and screening practices in the border region and the city of El Paso
need improvements. These include changes from the local level where data is collected and
reported, all the way up to the funding agencies who develop objectives and goals for health
programs and agencies.
T-ALL is a hematological malignancy that is tied to several environmental factors and
living conditions. Preventing the incidence of this disease would require safety regulations and
needs assessments in the industries that have workers at risk of exposures to leukemogens.
The GRK-5 and -6 genes may be dysregulated in T-ALL due to mutations, but further
studies are needed to quantify their relative expression and identify possible mediators of the
CCR7-CCL-19/-21 signaling pathway. The CRISPR experimental results showed no reduction in
the expression of GRK-5 or -6, but GRK-6 may have been partially reduced after esiRNA
nucleofection, which could provide an alternative to test the chemotactic properties of the T-ALL
cells that do not express GRK-6.
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CHAPTER 5: MPH CORE COMPETENCIES
The following competencies of the Master’s in Public Health Program will be covered in this
project:

HISPANIC AND BORDER HEALTH
The city of El Paso, Texas is populated in its majority by a Hispanic population.
Hispanics have been disproportionally affected by T-ALL, which makes them an appropriate
target for public health interventions to increase cancer awareness and preventive practices.

BIOSTATISTICS
The current national relative risks, odds ratios, incidence, and prevalence data of T-ALL
can be used as baselines to compare against the rates of the population in the city of El Paso.

EPIDEMIOLOGY
Gathering the region’s data including socioeconomics, education, health awareness, risk
factors, and environmental risks, among other measures, can positively influence the design and
effectiveness of programs offered by health care providers. These results can help promote the
interventions needed to address public health needs in the region.
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CHAPTER 6: HEALTHY PEOPLE 2020 OBJECTIVES
The Healthy People initiative is a joint effort among several federal level agencies who
work towards improving the general quality of life of the US population. This joint effort also
applies the obtained knowledge and data to educate the people about health risks and potential
hazards that are affecting or could affect their health. Some of the more notable agencies
involved are: The Center for Disease Control, The Food and Drug Administration, The National
Institute of Health, The Agency for Healthcare Research, and The US Department of Education
among others.
The general strategy of these organizations is to develop sets of health-related objectives
to address in the country for periods of 10-years since the 1990s. New objectives and strategies
have been added as time goes on, and these interventions help to reduce health disparities that
are found in the population. New objectives are created according to current or developing health
problems which are addressed as needed in a progressive effort to reduce incidence and burden
of disease.

Some of the current relevant objectives to this project are:
C-1 Reduce the overall cancer death rate
C-13 Increase the proportion of cancer survivors who are living 5 years or longer after
diagnosis
C-14 (Developmental) Increase the mental and physical health-related quality of life of
cancer survivors
C-18 Increase the proportion of adults who were counseled about cancer screening
consistent with current guidelines
The current healthy people 2020 objectives are focused on colorectal, breast, and cervical cancer,
while there is no mention about any type of leukemia, even when it is the primary cause of
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cancer deaths in US children under the age of 22. The set of health objectives for the Healthy
People 2030 period does not include research and data collection efforts to address T-ALL cases.
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CHAPTER 7: HISPANIC/BORDER HEALTH CONCENTRATION COMPETENCIES
1. State and discuss the current major communicable, non-communicable, and environmental
public health threats in Hispanic and border communities.
Hispanic communities are statistically disproportionally affected by health conditions
such as HIV/AIDS, Diabetes, Cardiovascular disease and several types of Cancer (Aviles-Santa,
2017; Rodriguez, 2014; Center for Disease Control and Prevention, 2017). Communicable
threats like HIV/STDs, and food-borne and air-borne diseases may be spread through the daily
transit of people and goods from one country into the other. Cancer, Diabetes, and heart disease
are major non-communicable causes of morbidity and mortality in the United States as well as
specifically for Hispanic populations (Healthy Border 2020, 2015), and these conditions require
individual and specific interventions to be addressed. Environmental threats include the intense
UV radiation that is typical of the desertic climates in this region, and others from local
industries such as refineries, whose byproducts may cause adverse health effects in the
population after prolonged exposure periods.

2. State the basic principles of prevention and control of communicable and non-communicable
disease; discuss how these principles can be modified to accommodate cultural values and
practices in Hispanic and border communities.
Disease awareness is the first step towards prevention and control of many medical
conditions. A confirmatory diagnosing can change the urgency with which a patient seeks
treatment and changes behavior. Communicable diseases require awareness and proper
containment to prevent further incidence among the population, as well as a specific treatment
regimen against the particular condition. Non-communicable diseases also require a diagnosis for

65

status awareness, but the strictness of treatment will vary depending on the specific medical
condition.
A cancer diagnosis requires a clinical confirmation of a tissue sample from a patient, but
the fear of being diagnosed and the lack of insurance are reasons for why people avoid
participating in screening programs (American Cancer Society, 2018). Epidemiological registries
about statistical indices of disease in El Paso can help document the burden of disease and could
be used to design preventive strategies against T-ALL. To address the lack of diagnostic
screening and data collection, physicians and public health workers have to increase cultural
competence to better influence their patient’s participation in screening programs, behavior
change, treatment adherence, and promotion of health literacy so that they can better understand
their condition and the caveats that come with it.

3. Identify and access public health data on communicable and non-communicable disease in
Hispanic and border communities.
Data about T-ALL in El Paso is relatively scarce since there are no specifically
designated agency or program to start this data collection process. According to the latest data
from the healthy Paso del Norte (2018), 35.6% of adults (18-64 years) in El Paso were
uninsured, which is a large difference from the national average of 12.2%. The total cancer
incidence in the city was 394.3 cases per 100,000 people, which was lower than the national
average (448.7 per 100,000). Nationally, the greatest incidences of leukemias have been
documented in border states and the north-western portion of the country, although there are
some high incidence areas in the north-east part of the country as well (Siegel, 2017). The NIH’s
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latest report shows a 68.8% 5-year survival rate, but the latest incidence rates have been rising
since 1992 with the latest measure showing 1.7 new cases per 100,000 individuals (NIH, 2017).

Figure 38. Annual age-adjusted rates per 1,000,000 people for ALL who are younger than 20 years of age in the
United States from 2001-2014 (Siegel, 2017).

Another disease of high importance for border health is HIV, which had an incidence of
15.8 cases per 100,000 people in 2017, and a prevalence of 303.8 per 100,000 people in El Paso.
Tuberculosis had an incidence of 5.1 cases per 100,000 people in 2017, but this is considerably
higher than the national average of 2.8 and did not meet the Healthy People 2020 target of 1 case
per 100,000 people.

4. Identify, access, and summarize the content of one or more current initiatives relevant to
border health.
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The Healthy Border 2020 initiative is a binational program between the United States and
Mexican governments (US-Mexico Border Health Commission) with a public health agenda that
addresses 5 main objectives. These are: chronic/degenerative disease, infectious disease,
maternal/child health, mental health/addiction, and injury prevention. The purpose of the
initiative is to support policy change through evidence-based and culturally competent
interventions that bring together health professionals, academics, and border stakeholders into
collaboration. This project is the continuation of the previous Healthy Border 2010 initiative
which had its own set of priorities at its time, but the main objective has continued to be the
coordination of a public health response in the binational, state, and local levels.

5. Identify health disparities and approaches to achieving health equity.
The disproportionate higher incidence for T-ALL in Hispanics requires public health
interventions to reduce the disparities observed in this population. Adults with lack of health
insurance (35%) and inability to afford to see a doctor (22.8%) are other problems in El Paso
which will prevent a portion of the population from seeking medical advice/treatment (Healthy
Paso del Norte, 2016; 2017). Several strategies are necessary to reduce the many disparities that
affect El Paso, but they must be addressed separately and specifically. A strategy against the high
incidence of leukemia would be to promote data collection and screening programs. To reduce
the inability to see a doctor, patients can be referred to health programs that are free of charge
and provided by local health agencies. Cultural competency and health literacy can promote
medical consultations and adherence to treatment for patients who have low participation or
interest in treatment programs (Rodriguez, 2014).
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